GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » EV-to-FCF

Surrozen (Surrozen) EV-to-FCF : 0.10 (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Surrozen EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Surrozen's Enterprise Value is $-3.94 Mil. Surrozen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-40.76 Mil. Therefore, Surrozen's EV-to-FCF for today is 0.10.

The historical rank and industry rank for Surrozen's EV-to-FCF or its related term are showing as below:

SRZN' s EV-to-FCF Range Over the Past 10 Years
Min: 0.1   Med: 0.78   Max: 1.1
Current: 0.1

During the past 4 years, the highest EV-to-FCF of Surrozen was 1.10. The lowest was 0.10. And the median was 0.78.

SRZN's EV-to-FCF is ranked better than
91.28% of 390 companies
in the Biotechnology industry
Industry Median: 4.475 vs SRZN: 0.10

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Surrozen's stock price is $8.9799. Surrozen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.330. Therefore, Surrozen's PE Ratio for today is At Loss.


Surrozen EV-to-FCF Historical Data

The historical data trend for Surrozen's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen EV-to-FCF Chart

Surrozen Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -2.63 1.18 0.33

Surrozen Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 0.95 0.84 0.72 0.33

Competitive Comparison of Surrozen's EV-to-FCF

For the Biotechnology subindustry, Surrozen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surrozen's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Surrozen's EV-to-FCF falls into.



Surrozen EV-to-FCF Calculation

Surrozen's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-3.939/-40.761
=0.10

Surrozen's current Enterprise Value is $-3.94 Mil.
Surrozen's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surrozen  (NAS:SRZN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Surrozen's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.9799/-21.330
=At Loss

Surrozen's share price for today is $8.9799.
Surrozen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.330.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Surrozen EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Surrozen's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Surrozen (Surrozen) Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).
Executives
Yang Li officer: Exec. Vice President, Research C/O SURROZEN, INC., 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Anna Berkenblit director 830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md director, 10 percent owner 1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai director 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh officer: Chief Scientific Officer 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory other: Former VP Business Development C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove officer: Chief Medical Officer 1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Charles O Williams officer: Chief Financial Officer C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel other: Former Director 4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse director 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158

Surrozen (Surrozen) Headlines

From GuruFocus

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-04-2023

Surrozen Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 07-10-2022

Surrozen Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-30-2022